Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT07473687
Recruiting Observational

Feasibility Study of Non-Contact Imaging-Based Physiological Monitoring in the Operating Room

NCT07473687 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Taipei Veterans General Hospital, Taiwan
Phase
Observational
Started
2026-01-08
Last updated
2026-03-16

Condition(s) studied

CholecystitisLiver NeoplasmsCholelithiasisInguinal Hernia

Investigational drug(s) / intervention(s)

Non-contact rPPG software

Non-contact rPPG software: A non-invasive, video-based software utilizing remote Photoplethysmography (rPPG) technology to estimate heart rate, blood pressure, and SpO2 by analyzing facial video captured via camera-enabled devices.

Study summary

This study aims to evaluate the feasibility and accuracy of a non-contact, camera-based physiological monitoring technology in a perioperative setting (including anesthesia induction, surgery, and recovery).Conventional vital sign monitoring tools-such as ECG leads, blood pressure cuffs, and pulse oximeters-require direct skin contact, which may pose risks of cross-infection or skin injury in vulnerable populations (e.g., newborns or elderly patients). This research utilizes remote Photoplethysmography (rPPG) technology to estimate vital signs, including heart rate, blood pressure, and blood oxygen saturation (SpO2), by analyzing facial video captured via standard camera devices (Logitech C930, iPhone 16 Pro Max, and Samsung Galaxy S24 Ultra).The primary goal is to assess the consistency and stability of this non-contact system compared to clinical gold-standard monitors (Masimo Root, SedLine O3, and Radical-7) during actual surgical procedures. The findings will serve as a foundation for developing non-invasive, supplementary monitoring tools in dynamic clinical environments.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients aged \>18 years. 2. Patients scheduled to undergo surgical procedures under general anesthesia. 3. American Society of Anesthesiologists (ASA) Physical Status I, II, or III. Exclusion Criteria: 1. Patients aged \< 18 years. 2. Pregnant patients. 3. Patients whose facial images cannot be captured or recognized (e.g., due to surgical drapes, severe edema, or major trauma). 4. Patients who refuse to participate or have not signed the informed consent form. 5. Other cases deemed unsuitable for the study by the clinical physician or anesthesiologist.

Primary outcome measure(s)

  • Accuracy of Heart Rate (HR) monitoring — From anesthesia induction to recovery (approximately 2-6 hours).
    The success rate of non-contact HR measurement using the rPPG software compared to the reference values from the Masimo Root clinical monitoring platform. A "success" is defined as an absolute error within +/- 3 bpm. Unit of Measure: Percentage of successful measurements (%)
  • Success rate of Systolic Blood Pressure (SBP) monitoring — From anesthesia induction to recovery (approximately 2-6 hours).
    The success rate of non-contact SBP measurement compared to the reference values from the Masimo Root platform. A "success" is defined as an absolute error within +/- 12 mmHg. Unit of Measure: Percentage of successful measurements (%)
  • Success rate of Diastolic Blood Pressure (DBP) monitoring — From anesthesia induction to recovery (approximately 2-6 hours).
    The success rate of non-contact DBP measurement compared to the reference values from the Masimo Root platform. A "success" is defined as an absolute error within +/- 10 mmHg. Unit of Measure: Percentage of successful measurements (%)
  • Success rate of Oxygen Saturation (SpO2) monitoring — From anesthesia induction to recovery (approximately 2-6 hours).
    The success rate of non-contact SpO2 measurement compared to the reference values from the Masimo Root platform. A "success" is defined as an absolute error within +/- 8% (when SpO2 \>/= 80%) or +/- 15% (when SpO2 \< 80%). Unit of Measure: Percentage of successful measurements (%)

Trial sites (1)

FacilityCityRegionStatus
Department of Anesthesiology, Taipei Veterans General Hospital Taipei Taiwan Recruiting

More Taipei Veterans General Hospital, Taiwan trials in Taiwan

Vancomycin Powder Combined With Autogenous Bone Graft as a Prevention for Post-operative Infection for Spine Surgery Recruiting
Waveform Periodicity Analysis in Patients With Persistent Atrial Fibrillation Recruiting
Exploring the Effects of Hand and Foot Exercise Intervention in Older Adults With Gynecological Cancer Receiving Chemotherapy Improvement of Peripheral Neuropathy and Quality of Life Starting soon
Transcranial Direct Current Stimulation for Depression Recruiting
Applying Breast Mask Containing Cabbage Leaves Extract to Relieve Breast Discomfort in Breastfeeding Women Starting soon

Other trials for the same condition

Dendritic Cell-immunotherapy for Advanced Hepatocellular Carcinoma Active, not recruiting
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07473687 on ClinicalTrials.gov ↗ ← All trials in Taiwan